www.hindu.com - Aug 22, 2008

Ahmedabad (PTI): Marck Biosciences will invest Rs 80 crore over the next three years to set up a new facility in Kheda district for manufacturing sterile dosage products.

The facility would make comprehensive range of formulations and injectibles in glass vials, sterile ointments, mono-dose Ophthalmics and an array of lens cleaning solutions for Global markets, a company release said on Thursday.

"With a wider and deeper portfolio of sterile dosages products, we will be able to address a larger share of the sterile dosage market both with our own brand and through contract manufacturing," company's Managing Director Bhavesh Patel said.

"Our existing facility has five Blow-Fill-Seal technology lines and we plan to add new technological capabilities to manufacture diverse range of sterile dosages products," Patel said.
With the investment of Rs 80 crore MBL's investment at Kheda facility would cross a total of Rs 220 crore, it said.

The company is also expecting growth in its revenue to over Rs 100 crore in 2008-09, it added.

The company would be launching its products in 15 more countries in the current financial year. MBL has its presence in over 55 countries at present, the release added.

MBL manufactures and markets the a range of sterile dosages, ophthalmics, respiratory, irrigation solutions and anti-infectives across India.